References of "Martinive, Philippe"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLA RADIOTHÉRAPIE DANS LE CANCER DU RECTUM CHEZ LA PERSONNE ÂGÉE: Quel bénéfice pour le traitement ?
MARTINIVE, Philippe ULg; ALLEPAERTS, Sophie ULg; VAN DAELE, Daniel ULg et al

in Revue Médicale de Liège (2014), 69(Supp 1), 47-52

Dans les années à venir, nous serons de plus en plus amenés à prendre en charge des patients âgés en oncologie. Dans ce contexte, quelles sont les évidences scientifiques à notre disposition qui nous ... [more ▼]

Dans les années à venir, nous serons de plus en plus amenés à prendre en charge des patients âgés en oncologie. Dans ce contexte, quelles sont les évidences scientifiques à notre disposition qui nous permettent de prendre en charge de façon correcte cette population oncologique âgée ? Les patients âgés présentent souvent de multiples co-morbidités pouvant interférer avec le traitement oncologique rendant d’autant plus complexe leur prise en charge. Le pic d’inci - dence du cancer du rectum se situe autour des 80 ans, loin au-dessus de l’âge moyen des patients inclus dans les études cliniques. La survie globale des patients traités pour un cancer du rectum s’est améliorée au cours de la dernière décennie, essentiellement pour des patients de moins de 75 ans. Le trai - tement du cancer du rectum nécessite une approche multidis - ciplinaire. L’évaluation gériatrique en fait partie intégrante. Elle permet de définir au mieux la stratégie thérapeutique en fonction de l’état général du patient, de son contexte neuro- psychologique, fonctionnel et social. La radiothérapie joue un rôle majeur dans le traitement du rectum. Quelle est sa place chez les personnes âgées ? Bénéficient-elles également de la radiothérapie, comme la population jeune sélectionnée dans les études contrôlées ? Quel est l’impact de ce traitement sur la qualité de vie ? Voilà des questions essentielles auxquelles nous allons tenter d’apporter une réponse [less ▲]

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailLA RADIOTHÉRAPIE DANS LE CANCER DU RECTUM : quand, comment et pourquoi ?
MARTINIVE, Philippe ULg; VAN DAELE, Daniel ULg; LENNERTS, Evelyne ULg et al

in Revue Médicale de Liège (2014), 69(Supp 1), 37-46

Depuis plusieurs décades, la radiothérapie préopéra - toire ou postopératoire joue un rôle important dans le contrôle local de l’adénocarcinome du rectum. Cette dernière décennie, avec la systématisation ... [more ▼]

Depuis plusieurs décades, la radiothérapie préopéra - toire ou postopératoire joue un rôle important dans le contrôle local de l’adénocarcinome du rectum. Cette dernière décennie, avec la systématisation de la chirurgie d’exérèse en totalité du mésorectum (TME), le profil de récidive locale du cancer du rectum a été fortement modifié. Dans un tel contexte, la place de la radiothérapie doit être réévaluée en tenant compte de ces modifications. Dans cet article, nous proposons de faire la revue des différentes grandes études concernant les techniques et les indications d’un traitement de radiothérapie pré- ou post opératoire dans le contexte d’une chirurgie rectale TME. [less ▲]

Detailed reference viewed: 44 (11 ULg)
Full Text
Peer Reviewed
See detailUTILISATION DE L’IMAGERIE FONCTIONNELLE EN RADIOTHÉRAPIE
LALLEMAND, François ULg; LAKOSI, Ferenc ULg; HUSTINX, Roland ULg et al

in Revue Médicale de Liège (2014), 69(Supp 1), 20-28

Les progrès technologiques réalisés par l’image- rie médicale l’ont placée au centre de la prise en charge des patients oncologiques, tant au niveau du diagnostic, du pro - nostic et du suivi que dans la ... [more ▼]

Les progrès technologiques réalisés par l’image- rie médicale l’ont placée au centre de la prise en charge des patients oncologiques, tant au niveau du diagnostic, du pro - nostic et du suivi que dans la prise en charge thérapeutique. En effet, l’imagerie représente, à l’heure actuelle, la pierre angulaire des traitements de radiothérapie. Les objectifs du radiothérapeute sont d’irradier le plus précisément possible la tumeur à dose curative, tout en évitant les organes sains. Pour y arriver, le radiothérapeute utilise de façon routinière l’imagerie anatomique (Scanner et IRM). Depuis quelques années, le développement des différentes imageries métabo - liques et fonctionnelles, comme l’imagerie par émission de positons (PET-CT) et la résonnance magnétique fonctionnelle, ouvrent de nouvelles possibilités thérapeutiques grâce aux informations qu’elles apportent sur la biologie des tumeurs. Cet article décrit, de manière non exhaustive, les différentes imageries anatomiques et métaboliques à la disposition du radiothérapeute. [less ▲]

Detailed reference viewed: 17 (3 ULg)
Full Text
Peer Reviewed
See detailLA RADIOBIOLOGIE POUR LES NÉOPHYTES
COUCKE, Philippe ULg; MARTINIVE, Philippe ULg

in Revue Médicale de Liège (2014), 69(Supp 1), 16-19

La radiothérapie moderne ne se base pas unique - ment sur l’exploitation des améliorations en informatique, imagerie et robotique. La meilleure distribution de la dose au niveau de la cible, avec ... [more ▼]

La radiothérapie moderne ne se base pas unique - ment sur l’exploitation des améliorations en informatique, imagerie et robotique. La meilleure distribution de la dose au niveau de la cible, avec l’épargne des tissus sains avoisinants, rend possible une nouvelle exploitation de concept de radio - biologie. L’exemple type est la redécouverte des traitements hypo-fractionnés. [less ▲]

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailOrthanc - Lightweight, Scriptable DICOM Server for Medical Image Management in Radiotherapy
JODOGNE, Sébastien ULg; SOBCZAK, Sonia ULg; DEVILLERS, Magali ULg et al

in Radiotherapy & Oncology (2013), 106(2), 488

High-quality radiotherapy (RT) treatment planning requires the combination of information arising from multiple medical imaging modalities. For this reason, RT implies the setup and the management of ... [more ▼]

High-quality radiotherapy (RT) treatment planning requires the combination of information arising from multiple medical imaging modalities. For this reason, RT implies the setup and the management of complex flows of images between the various modalities and software of the hospital. Even though biomedical images are most commonly stored and transferred using the DICOM standard, it remains hard to automatize and optimize these clinical flows that are very specific to each hospital. This stems from the fact that programming the DICOM network protocol requires both a high level of familiarity with the DICOM standard as well as substantial experience in computer programming. This motivates the introduction of the Orthanc software in the medical practice to improve the RT imaging workflow. [less ▲]

Detailed reference viewed: 52 (8 ULg)
Full Text
See detaildoes neoadjuvant radiotherapy promote tumor dissemination ,
Leroi, Natacha ULg; boujouf, Sarah; COUCKE, Philippe ULg et al

Poster (2011, January)

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailNew indications for radiotherapy: primary liver cancer and secondary liver oligometastases
JANVARY, Zsolt Levente ULg; JANSEN, Nicolas ULg; MARTINIVE, Philippe ULg et al

in Belgian Journal of Medical Oncology [=BJMO] (2011), 5(1), 8-13

Surgery is considered to be the standard treatment for intrahepatic malignancies, primary <br />cancers and metastatic lesions. However, a great many patients are not eligible for surgical <br ... [more ▼]

Surgery is considered to be the standard treatment for intrahepatic malignancies, primary <br />cancers and metastatic lesions. However, a great many patients are not eligible for surgical <br />intervention. Modern stereotactic radiotherapy has the potential to be an effective alternative <br />treatment modality with low toxicity for patients with primary hepatocellular carcinoma <br />and liver oligometastases. In this paper we intend to review the current status and published <br />experiences in the field of liver irradiation. [less ▲]

Detailed reference viewed: 52 (7 ULg)
Full Text
Peer Reviewed
See detail4DCT EVALUATION OF THE RESPIRATORY-RELATED MOVEMENT OF THE BREAST USING SURGICAL CLIPS AS FIDUCIALS
JANVARY, Zsolt Levente ULg; Broens, Audrey; MARTINIVE, Philippe ULg et al

Poster (2010, September)

To explore the respiratory-related displacement of the tumour bed in patients undergoing breast conserving <br />surgery followed by external-beam radiotherapy, by using respiratory correlated imaging and ... [more ▼]

To explore the respiratory-related displacement of the tumour bed in patients undergoing breast conserving <br />surgery followed by external-beam radiotherapy, by using respiratory correlated imaging and surgical clips as fiducials. [less ▲]

Detailed reference viewed: 30 (3 ULg)
Full Text
Peer Reviewed
See detailEVALUATION OF THE AUTOMATIC IMAGE REGISTRATION FEATURES OF A KV CONE-BEAM CT IMAGING SYSTEM
JANVARY, Zsolt Levente ULg; JANSEN, Nicolas ULg; MATHOT, Michel ULg et al

in Radiotherapy & Oncology (2010), 96(supp 1),

Detailed reference viewed: 36 (11 ULg)
Full Text
See detailEVALUATION OF THE AUTOMATIC IMAGE REGISTRATION FEATURES OF A KV CONE-BEAM CT IMAGING SYSTEM
JANVARY, Zsolt Levente ULg; JANSEN, Nicolas ULg; MATHOT, Michel ULg et al

Poster (2010, September)

As a part of the clinical implementation of a kV cone-beam CT (CBCT) volumetric imaging system for new Elekta Synergy linear accelerators, the automatic image registration (IR) system of the XVI Software ... [more ▼]

As a part of the clinical implementation of a kV cone-beam CT (CBCT) volumetric imaging system for new Elekta Synergy linear accelerators, the automatic image registration (IR) system of the XVI Software was studied. We examined the effect of the variability of matching parameters of the software on the results of the patient position errors. [less ▲]

Detailed reference viewed: 38 (11 ULg)
Full Text
Peer Reviewed
See detailIdentification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases.
Daneau; Boidot; MARTINIVE, Philippe ULg et al

in Clinical Cancer Research : An Official Journal of the American Association for Cancer Research (2010), 16(2), 410-419

Purpose: Cyclic hypoxia in tumors originates from heterogeneities in RBC flux and influences not only tumor cells but also endothelial cells lining tumor blood vessels. Whether pO2 fluctuations ... [more ▼]

Purpose: Cyclic hypoxia in tumors originates from heterogeneities in RBC flux and influences not only tumor cells but also endothelial cells lining tumor blood vessels. Whether pO2 fluctuations, particularly transient reoxygenation periods, alter the well-known hypoxia-inducible factor (HIF)–dependent gene program is largely unknown. Experimental Design: We compared the transcriptomic profiles of endothelial and tumor cells exposed to cyclic hypoxia versus continuous hypoxia to uncover a possible differential effect on angiogenesis and metastases. Results: Microarray analyses identified early genes that were selectively induced by cyclic hypoxia in endothelial cells. Among them, we focused on PTGS2 because the observed increase in mRNA expression led to a significant increase in the expression and activity of cyclooxygenase-2 (COX-2; the protein product of PTGS2). HIF-1α was shown to be stabilized by cyclic hypoxia (despite reoxygenation periods) and to favor COX-2 induction as validated by the use of echinomycin and HIF-1α targeting small interfering RNA. Using a specific COX-2 inhibitor and a dedicated COX-2 targeting small interfering RNA, we documented that COX-2 accounted for the higher endothelial cell survival and angiogenic potential conferred by cyclic hypoxia. Cyclic hypoxia also led to a preferential COX-2 induction in tumor cells and, contrary to continuous hypoxia, fostered a higher metastatic take of prechallenged tumor cells. Conclusions: Our study documents that PTGS2/COX-2 is part of a cyclic hypoxia gene signature and largely accounts for the unique phenotype of endothelial and tumor cells exposed to fluctuations in pO2, thereby offering new perspectives for the clustering of tumors expressing COX-2 together with other cyclic hypoxia-responsive genes. Clin Cancer Res; 16(2); 410–9 [less ▲]

Detailed reference viewed: 49 (8 ULg)
Full Text
Peer Reviewed
See detailLa vascularisation tumorale en tant que source de résistance aux traitements de radiothérapie et chimiothérapie
MARTINIVE, Philippe ULg; COUCKE, Philippe ULg

in Revue Médicale de Liège (2010), 65(3), 133-139

Angiogenesis is a hallmark of tumours. The newly formed tumour vessels are structurally and functionally abnormal leading to tumour perfusion heterogeneities and subsequently to the development of hypoxic ... [more ▼]

Angiogenesis is a hallmark of tumours. The newly formed tumour vessels are structurally and functionally abnormal leading to tumour perfusion heterogeneities and subsequently to the development of hypoxic areas. Generally, tumour hypoxia refers to an increasing distance between vasculature and tumour cells (i.e. chronic hypoxia). Chronic hypoxia promotes tumour resistance to treatments and metastasis. The temporal aspect of hypoxia is completely neglected in chronic hypoxia. Intermittent hypoxia (HI) takes the transient and temporal aspect of hypoxia into account. HI is defined as pO2 fluctuations in tumour vessels secondary to transient arrest of tumour blood flow. IH extends the concept of tumour hypoxia to tumour vessels and vascular cells. Transient arrest of tumour blood flow promotes tumour resistance to radio- and chemotherapy treatments and favours metastasis. Moreover, IH protects tumour vessels and endothelial cells against pro-apoptotic stresses and promotes angiogenesis. A comprehensive dissection of the mechanisms leading to IH allows the development and establishment of new therapeutic approaches. [less ▲]

Detailed reference viewed: 92 (7 ULg)
Full Text
Peer Reviewed
See detailImpact of cyclic hypoxia on HIF-1a regulation in endothelial cells: new insights for anti-tumor treatments
Martinive, Philippe ULg

in FEBS Journal (2008)

Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells - new insights for anti-tumor treatments.Martinive P, Defresne F, Quaghebeur E, Daneau G, Crokart N, Grégoire V, Gallez B, Dessy C ... [more ▼]

Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells - new insights for anti-tumor treatments.Martinive P, Defresne F, Quaghebeur E, Daneau G, Crokart N, Grégoire V, Gallez B, Dessy C, Feron O. Unit of Pharmacology and Therapeutics, Université catholique de Louvain, Brussels, Belgium. Heterogeneities in tumor blood flow are associated with cyclic changes in pO(2) or cyclic hypoxia. A major difference from O(2) diffusion-limited or chronic hypoxia is that the tumor vasculature itself may be directly influenced by the fluctuating hypoxic environment, and the reoxygenation phases complicate the usual hypoxia-induced phenotypic pattern. Here, we determined the cyclic hypoxia-driven pathways that modulate hypoxia inducible factor (HIF)-1alpha abundance in endothelial cells to identify possible therapeutic targets. We found that exposure of endothelial cells to cycles of hypoxia/reoxygenation led to accumulation of HIF-1alpha during the hypoxic periods and the phosphorylation of protein kinase B (Akt), extracellular regulated kinase (ERK) and endothelial nitric oxide synthase (eNOS) during the reoxygenation phases. We identified stimulation of mitochondrial respiration and activation of the phosphoinositide-3 kinase (PI3K)/Akt pathway during intervening reoxygenation periods as major triggers of the stabilization of HIF-1alpha. We also found that the NOS inhibitor nitro-l-arginine methyl ester further stimulated the cyclic hypoxia-driven HIF-1alpha accumulation and the associated gain in endothelial cell survival, thereby mirroring the effects of a PI3K/Akt inhibitor. However, combination of both drugs resulted in a net reduction in HIF-1alpha and a dramatic in decrease in endothelial cell survival. In conclusion, this study identified cyclic hypoxia, as reported in many tumor types, as a unique biological challenge for endothelial cells that promotes their survival in a HIF-1alpha-dependent manner through phenotypic alterations occurring during the reoxygenation periods. These observations also indicate the potential of combining Akt-targeting drugs with anti-angiogenic drugs, in particular those interfering with the NO pathway. PMID: 19077164 [PubMed - as supplied by publisher [less ▲]

Detailed reference viewed: 54 (9 ULg)
Full Text
Peer Reviewed
See detail(19) F NMR in vivo spectroscopy reflects the effectiveness of perfusion - enhancing vascular modifiers for improving gemcitabine chemotheraypy
Cron, Greg O.; Ansiaux; MARTINIVE, Philippe ULg et al

in Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine (2008)

Laboratory of Biomedical Magnetic Resonance and Laboratory of Medicinal Chemistry and Radiopharmacy, Université Catholique de Louvain, UCL, Brussels, Belgium. Nuclear magnetic resonance spectroscopy of ... [more ▼]

Laboratory of Biomedical Magnetic Resonance and Laboratory of Medicinal Chemistry and Radiopharmacy, Université Catholique de Louvain, UCL, Brussels, Belgium. Nuclear magnetic resonance spectroscopy of fluorine-19 ((19)F NMR) has proven useful for evaluating kinetics of fluorinated chemotherapy drugs in tumors in vivo. This work investigated how three perfusion-enhancing vascular modifiers (BQ123, thalidomide, and Botulinum neurotoxin type A [BoNT-A]) would affect the chemotherapeutic efficacy of gemcitabine, a fluorinated drug widely used in human cancer treatment. Murine tumor growth experiments demonstrated that only BoNT-A showed a strong trend to enhance tumor growth inhibition by gemcitabine (1.7 days growth delay, P = 0.052, Student t-test). In accord with these results, (19)F NMR experiments showed that only BoNT-A increased significantly the uptake of gemcitabine in tumors (50% increase, P = 0.0008, Student t-test). Further experiments on gemcitabine kinetics (NMR vs time) and distribution ((19)F MRI) confirmed the uptake-enhancing properties of BoNT-A. The results of this study demonstrate that (19)F NMR can monitor modulation of the pharmacokinetics of fluorinated chemotherapy drugs in tumors. The results also show that (19)F NMR data can give a strong indication of the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy in murine tumors. (19)F NMR is a promising tool for preclinical evaluation of such vascular modifiers and may ultimately be used in the clinic to monitor how these modifiers affect chemotherapy. 2007 Wiley-Liss, Inc PMID: 18050344 [PubMed - indexed for MEDLINE] [less ▲]

Detailed reference viewed: 48 (8 ULg)